Volume 72, Issue 8, Pages 912-913 (October 2007) A cost too high to bear? Prophylaxis versus preemptive therapy to prevent post- transplantation cytomegalovirus M.D. Pescovitz Kidney International Volume 72, Issue 8, Pages 912-913 (October 2007) DOI: 10.1038/sj.ki.5002444 Copyright © 2007 International Society of Nephrology Terms and Conditions
Figure 1 What is the most cost-effective modality to prevent cytomegalovirus infection? The cytomegalovirus is an encapsulated DNA virus. Two primary modalities are used to prevent the development of cytomegalovirus disease after transplantation: prophylaxis and preemptive therapy. Cost consideration is a major driver in the choice between the two approaches. Figure adapted from ref. 14. Kidney International 2007 72, 912-913DOI: (10.1038/sj.ki.5002444) Copyright © 2007 International Society of Nephrology Terms and Conditions